Cullinan Therapeutics, Inc. Common Stock
CGEMCullinan Therapeutics, Inc. (CGEM) is a biotechnology company focused on developing gene editing and gene therapy technologies to treat genetic and chronic diseases. The company aims to leverage advanced research platforms to create innovative therapeutic solutions with a focus on precision medicine.
Company News
Cullinan Therapeutics presented preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, demonstrating potential for B cell depletion across multiple autoimmune diseases like rheumatoid arthritis, Sjögren's disease, and systemic lupus erythematosus.
Amgen's rocatinlimab outperformed placebo in an atopic dermatitis trial, but the data fell short of market leader Dupixent's results, raising concerns about its competitiveness. Uplizna, Amgen's treatment for myasthenia gravis, showed promising results in a Phase 3 trial, with potential advantages like less frequent dosing.
Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.
The company's presentation at a conference got the attention of analysts and investors.
Cullinan is trading way below cash, which often means the market thinks the company lacks growth prospects. Read more to see why I rate CGEM stock a Hold.
